Oncotelic Therapeutics Statistics
Total Valuation
Oncotelic Therapeutics has a market cap or net worth of 9.25 million. The enterprise value is 21.12 million.
| Market Cap | 9.25M |
| Enterprise Value | 21.12M |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncotelic Therapeutics has 406.27 million shares outstanding. The number of shares has increased by 2.12% in one year.
| Shares Outstanding | 406.27M |
| Shares Change (YoY) | +2.12% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 49.11% |
| Owned by Institutions (%) | n/a |
| Float | 186.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 130.06 |
| PB Ratio | 0.76 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.05 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01, with a Debt / Equity ratio of 109.56.
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | 109.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.43 |
Financial Efficiency
Return on equity (ROE) is -12.83% and return on invested capital (ROIC) is -0.94%.
| Return on Equity (ROE) | -12.83% |
| Return on Assets (ROA) | -0.76% |
| Return on Capital (ROIC) | -0.94% |
| Revenue Per Employee | 3,182 |
| Profits Per Employee | -56,327 |
| Employee Count | 22 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.69% in the last 52 weeks. The beta is -0.21, so Oncotelic Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | -0.21 |
| 52-Week Price Change | -29.69% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 47.98 |
| Average Volume (20 Days) | 266,072 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Oncotelic Therapeutics had revenue of 70,000 and -1.24 million in losses. Loss per share was -0.00.
| Revenue | 70,000 |
| Gross Profit | 70,000 |
| Operating Income | -362,787 |
| Pretax Income | -1.50M |
| Net Income | -1.24M |
| EBITDA | n/a |
| EBIT | -362,787 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 72,216 in cash and 12.60 million in debt, giving a net cash position of -12.53 million or -0.03 per share.
| Cash & Cash Equivalents | 72,216 |
| Total Debt | 12.60M |
| Net Cash | -12.53M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | 11.50M |
| Book Value Per Share | 0.03 |
| Working Capital | -16.01M |
Cash Flow
| Operating Cash Flow | -1.11M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -518.27% |
| Pretax Margin | -2,147.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncotelic Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.12% |
| Shareholder Yield | -2.12% |
| Earnings Yield | -13.83% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Oncotelic Therapeutics has an Altman Z-Score of -1.83. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.83 |
| Piotroski F-Score | n/a |